After hours:
Chart Events
Performance Outlook
| Previous Close | 91.26 |
| Open | 91.02 |
| Bid | 91.35 x 900 |
| Ask | 91.82 x 1000 |
| Day's Range | 90.59 - 91.47 |
| 52 Week Range | 79.09 - 95.17 |
| Volume | |
| Avg. Volume | 2,590,377 |
| Market Cap | 202.364B |
| Beta (5Y Monthly) | 0.51 |
| PE Ratio (TTM) | 8.52 |
| EPS (TTM) | 10.73 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.33 (3.64%) |
| Ex-Dividend Date | Mar 08, 2022 |
| 1y Target Est | 104.40 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NVS
Related Research
- Novartis AGAnalyst Report: Novartis AGNovartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The firm sells its products globally, with the United States representing close to one third of total revenue.RatingFair ValueEconomic Moat9 days agoMorningstar
- GlobeNewswire
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from Kymriah treatment demonstrated – of patients who achieved a complete response, 85% were still in response at 12 months1 Kymriah can be administered in the outpatient setting, offering increased flexibility and potentially reducing the burden of therapy for patients and their care teams1,2 Kymriah is now FDA
- GlobeNewswire
Sandoz appoints new Board representative to global AMR Industry Alliance
Dr. Boumediene Soufi, global head of Sandoz AMR (antimicrobial resistance) program, to represent Sandoz as Board member of AMR Industry Alliance (AMRIA)The Alliance brings together about 100 life science companies / associations in search of sustainable solutions to curb AMRSandoz, as largest global provider of generic antibiotics1, is committed to a pragmatic and balanced approach to address this growing global health threat Basel, May 27, 2020 — Sandoz is pleased to announce the appointment of
- Insider Monkey
Mario Gabelli is Selling These 15 Stocks in 2022
In this article, we will look at the top 15 stocks sold by investing legend Mario Gabelli in Q1 2022. If you want to see the top 5 stocks sold by Gabelli in Q1, go to Mario Gabelli is Selling These 5 Stocks in 2022. Mario Gabelli is an Italian-American investor, financial analyst, and hedge […]
